1.2 ML garadacimab-gxii 167 MG/ML Auto-Injector — RxCUI 2717175
RxNorm drug concept · Semantic clinical drug
RxCUI 2717175
Semantic clinical drug · SCD
● Current RxNorm concept 1 FDA product
1 package NDC
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2717175
Official name1.2 ML garadacimab-gxii 167 MG/ML Auto-Injector
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asgaradacimab-gxii 200 MG per 1.2 ML Auto-Injector; garadacimab-gxii 200 MG in 1.2 ML Auto-Injector
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)54 prescriptions · 4 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
🕸️ Concept Web — How 1.2 ML garadacimab-gxii 167 MG/ML Auto-Injector Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
1.2 ML garadacimab-gxii 167 MG/ML Auto-Injector
RxCUI 2717175 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Garadacimab
2717169IN -
Garadacimab-gxii
2717168PIN
-
Garadacimab
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Andembry
2717177BN
-
Andembry
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Garadacimab Auto-Injector
2717172SCDF -
Garadacimab-gxii Auto-Injector
2717174SCDFP -
Garadacimab Injectable Product
2717171SCDG -
Garadacimab-gxii Injectable Product
2717173SCDGP -
Garadacimab Auto-Injector [Andembry]
2717180SBDF -
Garadacimab-gxii Auto-Injector [Andembry]
2717181SBDFP -
Andembry Injectable Product
2717179SBDG -
Auto-Injector
1649570DF - +1 more in this family
-
Garadacimab Auto-Injector
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Garadacimab-gxii 167 MG/ML
2717170SCDC -
1.2 ML garadacimab-gxii 167 MG/ML Auto-Injector [Andembry]
2717182SBD -
Garadacimab-gxii 167 MG/ML [Andembry]
2717178SBDC
-
Garadacimab-gxii 167 MG/ML
Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Garadacimab-gxii 167 MG/ML
SCDC · 2717170 -
Garadacimab Auto-Injector
SCDF · 2717172 -
Garadacimab-gxii Auto-Injector
SCDFP · 2717174 -
Garadacimab Injectable Product
SCDG · 2717171 -
Garadacimab-gxii Injectable Product
SCDGP · 2717173
Brand-Name Concepts
-
1.2 ML garadacimab-gxii 167 MG/ML Auto-Injector [Andembry]
SBD · 2717182 -
Garadacimab-gxii 167 MG/ML [Andembry]
SBDC · 2717178 -
Garadacimab Auto-Injector [Andembry]
SBDF · 2717180 -
Garadacimab-gxii Auto-Injector [Andembry]
SBDFP · 2717181 -
Andembry Injectable Product
SBDG · 2717179 -
Andembry
BN · 2717177
📦 FDA Products & Package NDCs
1 product · 1 package NDC
1 package NDC map to RxCUI 2717175 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 63833-0925-01 | 1 SYRINGE, GLASS in 1 CARTON (63833-925-01) / 1.2 mL in 1 S... | ANDEMBRY | CSL | 2025-06-16 |
Observed labelers:
CSL (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.